REFERENCES
- Ferrari S, Dondi M, Fanti S, et al. Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm 2003; 18: 847–851
- Jenkins S A, Kynaston H G, Davies N D, Baxter J N, Nott D M. Somatostatin analogs in oncology: A look to the future. Chemotherapy 2001; 47(Suppl 2)162–196.
- Bohuslavizki K H, Brenner W, Braunsdorf W E, et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996; 17: 302–310.
- Guyotat J, Champier J, Jouvet A, et al. Differential expression of somatostatin receptors in ependymoma: Implications for diagnosis. Int J Cancer 2001; 95: 144–151
- Guyotat J, Champier J, Pierre G S, et al. Differential expression of somatostatin receptors in medulloblastoma. J Neurooncol 2001; 51: 93–103
- Fruhwald M C, Rickert C H, O’Dorisio M S, et al. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res 2004; 10: 2997–3006
- Muller H L, Fruhwald M C, Scheubeck M, et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol 1998; 38: 27–40
- Beutler D, Avoledo P, Reubi J C, et al. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 2005; 103: 869–873
- Glas M, Hennemann B, Hirschmann B, et al. Complete response after treatment with a somatostatin analogue in an adult patient with recurrent medulloblastoma. Acta Oncol 2008; 47: 479–480
- Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994; 218: 314–319
- Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R, et al. (99m)Tc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: Results of 3 years’ experience. Eur J Nucl Med Mol Imaging 2006; 33: 1123–1133
- Storch D, Behe M, Walter M A, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: Does tumor or pancreas uptake correlate with the rate of internalization?. J Nucl Med 2005; 46: 1561–1569
- Geoerger B, Kerr K, Tang C B, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61: 1527–1532
- Vaidyanathan G, Boskovitz A, Shankar S, Zalutsky M R. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: Potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides 2004; 25: 2087–2097
- Vaidyanathan G, Friedman H S, Affleck D J, Schottelius M, Wester H J, Zalutsky M R. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin Cancer Res 2003; 9: 1868–1876
- Ottesen L H, Flyvbjerg A, Jakobsen P, Bendtsen F. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997; 26: 1018–1025
- Li M, Zhang R, Li F, et al. Transfection of SSTR-1 and SSTR-2 inhibits Panc-1 cell proliferation and renders Panc-1 cells responsive to somatostatin analogue. J Am Coll Surg 2005; 201: 571–578
- Stone A A, Chambers T C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254: 110–119